Related Experiment Video
Updated: Mar 23, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
[Hepatitis C infection: Therapeutic strategies]
Thierno Diatta1, Delphine Chavade1, Françoise Degos1
1Haute Autorité de santé, service évaluation du médicament, 5, avenue du Stade-de-France, 93218 Saint-Denis La Plaine cedex, France.
Presse Medicale (Paris, France : 1983)
|March 24, 2016
Summary
New direct-acting antiviral regimens offer a highly effective standard of care for chronic hepatitis C, achieving high sustained viral response rates. These treatments represent a significant advancement, particularly for patients with unmet needs.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C treatment historically relied on interferon-based combinations.
- Direct-acting antivirals (DAAs) have revolutionized hepatitis C management.
- Previous treatments had limitations in efficacy and tolerability.
Purpose of the Study:
- To review clinical data on direct-acting antivirals for chronic hepatitis C.
- To discuss current and emerging treatment regimens.
- To highlight the impact of DAAs on patient outcomes.
Main Methods:
- Review of clinical trial data and published literature on DAAs.
- Analysis of treatment outcomes, including sustained viral response rates.
- Discussion of DAA combinations with or without ribavirin.
Main Results:
- DAA combinations achieve sustained viral response rates exceeding 90% in most patients.
- A 12-week treatment duration is effective for the majority of patients, including those with uncomplicated cirrhosis.
- DAAs offer a new era for patients ineligible or non-responsive to interferon/ribavirin.
Conclusions:
- Direct-acting antiviral combinations are the new standard of care for chronic hepatitis C.
- Further research is needed for specific populations with limited data (e.g., complicated cirrhosis, transplant patients, renal failure).
- Ongoing development aims for shorter treatment durations and simplified therapeutic approaches.
Related Concept Videos
01:25Hepatitis
29
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
29
01:30Inhibitors of Viral Protein Synthesis
15
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
15
01:10Retrovirus Life Cycles
50.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
01:26Pharmaceutical Poisoning: Treatment Strategies
147
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
147
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
01:28Pulmonary Tuberculosis V
753
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
753